| INTRODUCTION
Prostate cancer (PCa) is the most common malignancy in men worldwide. 1 Androgen deprivation therapy (ADT) is one of the standard tools of care for patients with PCa. Neoadjuvant hormonal therapy (NHT) based on androgen deprivation is administered to improve the successful rate and prognosis of local therapy, including radical prostatectomy (RP) and radiotherapy, in patients with PCa. 2, 3 There is general agreement that positive surgical margin or extraprostatic extension in RP specimens in patients with low grade and stage PCa is relatively rare, and outcome in these patients is favorable. 4 Therefore, NHT is usually selected for patients with high-risk PCa, as well as some with patients with intermediate-risk PCa. However, some patients with low-risk PCa have been administered NHT for a variety of reasons, for example, anxiety due to waiting periods or the patient's wishes. Unfortunately, the anti-cancer effects of NHT in patients with low-risk PCa are not fully understood, because such patients are relatively rare. Similarly, the influences of NHT on pathological characteristics and cancer-related factors according to risk grade
have not yet been investigated.
Up-regulation of lymphangiogenesis leads to increased risk of metastasis and worse prognosis in various types of cancer. 5, 6 The most well-known and strongest regulators of cancer-related lymphangiogenesis are vascular endothelial growth factor (VEGF)-C and VEGF-D. 7, 8 The expressions of VEGF-C and VEGF-D in human prostate cancer tissues were reported to be positively associated with the metastatic spread of cancer cells. 9, 10 On the other hand, several investigators showed that the expressions of VEGF-C and VEGF-D in an androgen-dependent prostate cancer cell line (LNCaP) were upregulated by androgen depletion. [11] [12] [13] In addition to such in vitro studies, the possibility that ADT may stimulate lymphangiogenesis has been reported in human prostate cancer tissues. 13 From these facts, we hypothesized that ADT might stimulate cancer cell dissemination via up-regulation of lymphangiogenesis in PCa.
In this study, we investigate the differences in pathological features and biochemical recurrence (BCR) between RP tissues from PCa patients who received NHT and those who did not receive NHT according to risk classification. Next, to analyze the detailed anticancer mechanism of NHT, lymphangiogenesis-related parameters and the expression of VEGF-C and VEGF-D were also compared between these two groups.
| MATERIALS AND METHODS

| Patients
We investigated 153 tissues (non-NHT group = 80 and NHT group = 73) from patients who underwent RP in the Nagasaki University Hospital. To match the clinicopathological features between the two groups, patients who had clinical or pathological invasion into the seminal vesicle or surrounding tissues, presence of metastasis, or a Gleason score (GS) of 10 were excluded. In addition,
we also excluded patients with a short duration of NHT (<3 months) or serum prostate-specific antigen (PSA) levels >90 ng/mL. 
| Evaluation of lymphangiogenesis-related factors
VEGF expression was semi-quantitatively analyzed as previously described. 15 To determine LVD and LVA, sections labelled with anti-D2-40 antibody were examined. For each tumor section, three to five hot spots in the field of view (ie, with the greatest density of positively stained vessels) were evaluated. LVD was defined as the number of positively stained vessels per high-power field. According to a previous report, 5 the terms intra-and peri-tumoral denote within the tumor mass and within an area of 500 µM from the tumor border, respectively. Evaluation and measurements were performed by computer-aided image analysis (WinROOF version 6.4; Mitani, Fukui, Japan). In similar to pathological features, necrotic or degenerated tissues were not evaluated for lymphangiogenesis-related factors.
| Statistical analyses
Results are expressed as mean ± SD. 3 | RESULTS
| Pathological features
As shown in Table 1 , all pre-operative parameters, such as serum PSA levels at diagnosis, GS of biopsy specimens, and clinical T stage, were higher in the NHT group than in the non-NHT group; however, these differences between the two groups were not significant ( Table 1) .
With regard to pathological features of the RP specimens, the frequency of lymph node metastasis in patients was higher in the NHT group (6.8%) than in the non-NHT group (1.1%); however, the difference did not reach statistical significance (Table 1 ; P = 0.075).
Furthermore, no other pathological parameter showed any statistical difference between the two groups ( Table 1) .
Relationships between pathological features and NHT in RP specimens according to D'Amico risk classification are shown in 
| Biochemical recurrence
Kaplan-Meier survival curves showed that the BCR-free survival rate in the NHT group was significantly worse compared to the non-NHT group in patients with low-risk disease (P = 0.022; Figure 1A ). There was no significant difference between the non-NHT and NHT groups in patients with intermediate-(P = 0.713; Figure 1B ) and high-risk disease (P = 0.732; Figure 1C) . A multivariate analysis model including D'Amico risk classification and NHT showed that NHT was not an independent predictive factor for BCR-free survival (hazard ratio = 1.45, 95% confidence interval = 0.85-2.49; P = 0.174).
| Lymphangiogenesis
Representative images of D2-40-positive lymph vessels in PCa tissues are shown in Figure 2 . In the non-NHT group, nearly all of the D2-40-positive vessels were relapsed and the intraluminal space was narrow (Figure 2A ). In particular, there were few lymph vessels with a lumen in the intra-tumoral area of samples from patients in the non-NHT group. In fact, we could not measure the LVA in the intratumoral area. In contrast, D2-40-positive lymph vessels in tissues from patients in the NHT group had a wider inner cavity compared to the non-NHT group ( Figure 2B ). In addition, freed from pressure by tumor mass and contained cancer cells were detected in non-NHT group ( Figure 2C ). The level of peri-LVD was significantly higher in the NHT group (10.3 ± 3.1) than in the non-NHT group (7.9 ± 4.0; P < 0.001).
When similar analyses were performed according to D'Amico risk classification, a significant difference was detected in low-risk patients (P < 0.001), but not in intermediate-or high-risk patients (P = 0.079 and NHT, neoadjuvant hormonal therapy; s-PSA, serum prostate-specific antigen.
a Data were showed as mean/SD. P = 0.108, respectively) ( Figure 3A) . In regard to the relationship between intra-LVD and D'Amico risk classification, a significant difference was detected in low-risk patients (P < 0.001), but not in intermediate-or high-risk patients (P = 0.199 and 0.754, respectively) ( Figure 3B ). Peri-LVA was significantly higher in the NHT group (481.8 ± 133.5) than in the non-NHT group (230.3 ± 104.9; P < 0.001), and this difference was significant across all D'Amico risk classifications ( Figure 3C ). However, the degree of difference in peri-LVA between the non-NHT and NHT groups decreased according to D'Amico risk classification ( Figure 3C ).
| Lymphangiogenesis-related factors
Across all risk groups, the IRS of VEGF-C expression was significantly higher in the NHT group (2.8 ± 1.3) than in the non-NHT group 
NHT, neoadjuvant hormonal therapy; LH-RH, luteinizing hormone-releasing hormone; MAB, maximum androgen blockage.
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In order to explain the mechanisms behind these findings, we investigated lymphangiogenesis-related parameters according to risk classification. Our results showed that LVA was significantly higher in the NHT group than in the non-NHT group in all risk classifications.
Intra-and peri-LVD were also significantly different between the non-NHT group and the NHT group, although only in patients with low-risk PCa. In short, all lymphangiogenesis-related parameters were higher in by androgen deprivation in vivo and in vitro. 12, 13 However, contrary to our expectation, there was no significant difference in the expressions of these factors between the non-NHT group and the NHT group in patients with low-risk PCa. From these results, we speculated that upregulated lymphangiogenesis played a minimal role for such phenomena in patients with low-risk PCa, although, unfortunately, we were unable to further pursue this question with our study design.
However, we paid special attention to the pressure from interstitial fluid and mechanical compression in the intra-and peri-tumoral areas.
In short, several previous reports and this study have shown that lymph vessels in PCa specimens from patients who did not receive ADT were small and collapsed compared to those from patients who did receive ADT, as well as normal prostate tissues. 13, 20, 21 Additionally, pressure from interstitial fluid and mechanical compression in the intra-and peri-tumoral areas have been proposed to explain these observations. 22, 23 In fact, our finding that LVA was higher in the NHT group than in the non-NHT group could be explained by the decrease in pressure and mechanical compression by NHT within and around the tumor mass. Furthermore, we also speculated that increased LVD in the NHT group could be explained through a similar mechanism. That is, extremely occluded lymph vessels within the intra-tumoral area in the non-NHT group could not be counted as LVD; however, obstructed lymph vessels by NHT were counted as LVD. Thus, the anti-cancer effects of NHT create a favorable microenvironment for lymph vessel invasion and cancer cell dissemination via cancer-related lymph vessels.
The major limitation of this study was the small sample size.
Another limitation is the inherent potential of bias due to its retrospective nature. However, the frequency of patients with low-risk PCa treated with RP after NHT is relatively rare. In addition, a prospective randomized trial of patients with low-risk PCa to confirm the anti-cancer effects of NHT, including changes to cancer-related factors, is difficult because low-risk PCa patients are usually treated with local therapy, including RP and radiotherapy, without NHT or active surveillance. Furthermore, a retrospective multi-center study would be inadequate for our study design, owing to differences in pathological diagnosis and methods of RP.
NHT is mainly performed in patients with intermediate-and highrisk PCa. Therefore, the clinical usefulness of our results might be limited. However, in addition to RP, NHT has been performed in patients receiving radiotherapy and cryotherapy. 3, 24 Furthermore, ADT administration was selected for patients with high age and severe complicated diseases in spite of low-risk PCa. Based on these facts, we believe that the results of this study provide key information in understanding the pathological changes precipitated by ADT and in discussing treatment strategies in PCa patients with low-risk disease.
| CONCLUSIONS
Our results demonstrated that NHT increased cancer progression and decreased BCR-free survival via up-regulation of lymphangiogenesisrelated parameters, such as LVD and LVA in patients with low-risk PCa.
On the other hand, the expressions of VEGF-C and VEGF-D in the NHT group were not different from the non-NHT group. Our results suggest that NHT for patients with low-risk PCa may increase the risk for BCR after RP.
